Background: The immunosuppressive drug rapamycin (RAPA) promotes the expansion of CD4 + CD25 high Foxp3 + regulatory T cells via mechanisms that remain unknown. Here, we studied expansion, IL-2R-c chain signaling, survival pathways and resistance to apoptosis in human Treg responding to RAPA.
Methodology/Principal Findings: CD4
+ CD25 + and CD4 + CD25 neg T cells were isolated from PBMC of normal controls (n = 21) using AutoMACS. These T cell subsets were cultured in the presence of anti-CD3/CD28 antibodies and 1000 IU/mL IL-2 for 3 to 6 weeks. RAPA (1-100 nM) was added to half of the cultures. After harvest, the cell phenotype, signaling via the PI3K/ mTOR and STAT pathways, expression of survival proteins and Annexin V binding were determined and compared to values obtained with freshly-separated CD4 
CD25
high Foxp3 + regulatory T cells (nTreg) are essential for maintaining tolerance to self and regulating immune responses to foreign antigens. Thus, Treg have been implicated in the pathogenesis of autoimmune diseases, transplant rejection and infectious diseases [1, 2] . However, Treg can also sabotage antigen-specific immune responses against tumors as well as microbes and have been proposed as a potential mechanism of immune suppression in patients with cancer or chronic HIV-1 infection [3] [4] [5] [6] .
Recent clinical studies suggest that in patients with autoimmune or allergic diseases, thymus-derived nTreg are reduced in numbers [7] and/or have reduced suppressive functions [8] [9] [10] 
+ Treg cells do not induce GVHD after major histocompatibility complex (MHC)-mismatched bone marrow transplantation but instead suppress GVHD induced by non-regulatory donor T cells [11, 12] . Importantly, a co-transfer of
CD4
+ CD25 + Treg cells neither interfered with stem cell engraftment [11, 13] nor abrogated the beneficial anti-tumor activity of donor T-cell infusions [13, 14] . These murine studies are encouraging and provide a solid rationale for investigations of in vitro expansion strategies and adoptive transfer of human Treg cells for therapy of T-cell mediated autoimmune diseases or transplant rejection.
Discrimination of Treg from CD4 + CD25 + effector non-Treg (conventional T cells or Tconv) and selective expansion of Treg on a clinical scale are limiting steps in the development of successful Treg-based immunotherapy. To date, no specific markers for human Treg have been identified and validated. Foxp3, a transcription factor considered by many as the Treg marker, appears to be also transiently expressed in activated Tconv [15] . We have depended on the isolation of CD4 +
CD25
high T-cell subset in our studies of human nTreg [16] . In contrast to murine cells, human CD25
high cells are not a clearly-defined, discrete population, because there exists a large and overlapping population of CD25 low/interm T cells. Thus, co-purification of these T cells with CD4 +
high Treg might be responsible for weak suppressor activity observed in studies of human CD4 + CD25 + cells isolated from peripheral blood of normal donors [17] . Others reported that removal of CD49d + /CD127 + cells yields a population of Foxp3 + Treg which is free of contaminating CD25
+ effector cells (18) . Because CD4
Treg represent a minor subset (,2%) of the peripheral CD4 + T cells in humans [16, 17] , their in vitro expansion from peripheral blood for clinical use represents a challenge. To date, human Treg used in therapy have been obtained from the cord blood [19] [20] [21] .
Approaches proposed for the elimination of non-Treg cells overgrowing in cultures of incompletely purified Treg include the use of the immunosuppressive drug rapamycin (sirolimus, RAPA). We and Battaglia et al have shown that RAPA selectively promotes expansion of human CD4
+ CD25 high Foxp3 + T cells endowed with potent suppressor function in normal donors, patients with cancer or those with diabetes [16, 22, 23] . Though RAPA has been reported to induce Treg-dependent immunosuppression in vitro and in vivo [24] [25] [26] [27] , the exact mechanism of its action on Treg cells remains largely unknown. We have recently reported that one of the mechanisms through which RAPA can enrich for CD4 + CD25 high Treg may be its ability to selectively induce apoptosis in TCR-activated CD4 +
+ Tconv [16] . In contrast, activated nTreg which are constitutively CD25 high Foxp3 high remain resistant to RAPA-mediated apoptosis [16] . These preliminary results suggest that although human Treg subsets may express many of the same surface markers or receptors and produce the same cytokines as conventional CD4
+

CD25
2 or CD4 + CD25 low T cells, proliferation of these T cell subsets in response to TCR-mediated signals and IL-2 might be differentially regulated. This divergent regulation via the distinct molecular pathways could be a key mechanism for maintaining the homeostatic balance between Treg and Tconv. Further, it could be exploited for selective in vitro or in vivo expansion of antigenspecific Treg or T effector cells for therapy of patients with T-cell mediated diseases.
In this manuscript, we first define optimal conditions for ex vivo expansion of human Treg in the presence of RAPA and then demonstrate differential effects of RAPA on Tconv and Treg with respect to the Bcl-2 family protein expression, utilization of the STAT vs. PI3K/mTOR pathways and the PTEN protein expression.
Results
Responses of Treg (CD4
+
CD25
+ Foxp3 + ) and conventional (CD4 + CD25 neg ) T cells to RAPA in the presence of CD3/ CD28 Ab crosslinking and IL-2
Our initial experiments indicated that RAPA can selectively promotes expansion of CD4
Foxp3
+ human Treg isolated from the peripheral circulation of normal donors and activated with anti-CD3/CD28 Ab+IL-2 [16] . The CD4 +
CD25
high T cell subset used in our experiments was previously shown to consist largely of Foxp3 + cells [3, 5, 16] . Cultured CD4 + CD25 + cells down-regulated surface expression of CD25 in the absence of RAPA (R0) ( Figure 1A , left panel). In contrast, the parallel RAPA-containing cultures (+R), were enriched in CD4 +
high T cells ( Figure 1A , right panel Figure 1C ). As also shown in Figure 1D for 
neg T cells become highly sensitive to apoptosis upon TCR and IL-2-mediated activation in the presence of RAPA and die.
Proliferation kinetics of Treg and conventional T cells+RAPA
Next, the proliferation kinetics of autologous CD4 +
CD25
+ and CD4 + CD25 neg T cell subsets6RAPA were monitored by determining absolute cell numbers weekly during a 3-week expansion period (Figure 2A, B) . The frequency of CD4
+
CD25
high T cells in these cultures was also determined by flow cytometry. CD4 + CD25 neg T cells proliferated readily in the absence of RAPA, reaching a substantial fold expansion by week 3 ( Figure 2A ). CD4
+
CD25
neg cells did not proliferate in the presence of RAPA ( Figure 2B ). In contrast, both CD4 +
+ and CD4 + CD25 high T cells showed high expansion in the presence of RAPA but did not proliferate in its absence ( Figure 2A ). As CD4 + CD25 + T cell subset consists largely of CD4 + CD25 high Treg (see Figure 2D ), the expansion rate of both these subsets is comparable in the presence of RAPA. subset in the RAPA-containing cultures after 3 weeks of incubation, the highest Treg purity (99%) was obtained in cultures containing 100 nM of RAPA ( Figure 2D ). 1 nM RAPA cultures contained a mean of 76%64 (SD) of CD4 +
high Treg (Table 1) .
Phenotypic characteristics of Treg expanded by RAPA
The phenotype of CD4 + CD25 + T cells expanded in +R cultures was significantly different from that of T cells outgrown in R0 cultures (data not shown). The latter were CD4 + CD25 neg and did not express Foxp3, CTLA-4 or GITR. On the other hand, the CD4 + CD25 high T cells expanded in +R cultures had the memory phenotype (CD45RO + (RA 2 )) and expressed the characteristic Treg markers, including Foxp3, CD62L, CTLA4 and GITR ( Figure 3 ). These cells were strongly positive for Fas and FasL, and showed expression of granzymes and TGF-b. Their phenotype was compared to that of freshly harvested, FACS-sorted CD4 + CD25 high cells, and the gating used in these experiments is illustrated in Figure 3 , with representative dot plots shown in Figure S1 . Several differences were identified between fresh and RAPA-expanded Treg ( Figure 3 + . No differences in this phenotypic profile occurred in cells cultured for 3 or 6 weeks (data not shown). There were no significant differences in the Treg phenotypic profile in +R cultures established at RAPA concentrations ranging from 1 to 100 nM of the drug (data not shown). Overall, T cells expanded +RAPA had the phenotype that resembled that of Treg present in the peripheral circulation of NC, as previously reported by us [16] .
Suppressor functions of Treg expanded by RAPA
To evaluate suppressive activity of CD4 + CD25 + T cells cultured6RAPA for 3 or 6 weeks, CFSE co-culture assays were performed. Suppressor (S) T cells (Treg) derived from the R0 or +R cultures were co-incubated with CFSE-labeled fresh autologous CD4 + CD25 neg or CD8 + CD25 neg responder T cells (ratio 1S:1RC) stimulated with OKT3 and anti-CD28 Abs in the presence of 150 IU/mL of IL-2. Nearly complete suppression of RC proliferation was mediated by CD4 + CD25 + Treg cells derived from 3 week cultures +RAPA ( Figure 4A ). Significantly weaker suppression (p,0.001) was mediated by Treg cells originating from R0 cultures ( Figure 4B and Table 2 ). The mean % suppression obtained in CFSE-based suppression assays for all the R0 and +R cultures is shown in Figure 4B , while suppression mediated by CD4 +
CD25
+ Treg cells of six NC cultured in the presence of various concentrations of RAPA is shown in Table 2 . Suppression of RC proliferation was nearly complete with Treg cells cultured with 100 nM RAPA. Treg cells cultured in 1 nM RAPA also mediated high levels of suppression, as shown in Figure 4C and Table 3 ).
Our results showed that CD4 + CD25 neg Tconv expanded in the absence of RAPA (R0) contained few functional suppressor Treg. When CD4 + CD25 neg T cells were co-cultured with autologous RC as controls in the presence of RAPA, they neither proliferated nor mediated suppression in CFSE assays. Thus, RAPA did not induce Treg in the CD4 + CD25 neg T cell subset (data not shown).
Expression of pro-and anti-apoptotic proteins in fresh and cultured T-cell subsets
Our results indicated that the CD4 + CD25 high Treg generated in +R cultures mediated potent suppression and were resistant to spontaneous and activation-induced apoptosis. Apoptosis-sensitive CD4 + CD25 neg T cells were eliminated in these cultures. To determine whether survival of TCR-activated Treg in the presence of RAPA was dependent on the BcL-2 family members, expression of Bcl-2, Bcl-xL and Bax proteins in T cells was analyzed by flow cytometry in the parallel +R and R0 cultures.
Expression levels (measured as MFI) of pro-apoptotic Bax and anti-apoptotic Bcl-xL or Bcl-2 were equal in the apoptosis-resistant fresh CD4
+ CD25 neg T-cells ( Figure 5 ). However, in the apoptosissensitive fresh CD4 + CD25 high T cells, expression levels of Bcl-2 and Bcl-xL were significantly lower than those of Bax, with the Bcl-2/Bax and Bcl-xL/Bax ratios of 1/6.5 to 1/7.3, respectively ( Figure 5 ). After culture in the presence of RAPA for 3 weeks, CD4
+ CD25 neg cells were strongly positive for Bax but lost Bcl-2 expression, with the Bcl-2/Bax and Bcl-xL/Bax ratios of 1/96 and 1/68, respectively. In contrast, in the CD4 + CD25 high T cells cultured with RAPA, the expression levels of anti-apoptotic Bcl-2 and Bcl-xL increased significantly (p,0.001), resulting in the Bcl-2/Bax and Bcl-xL/Bax ratios of 1/2.6 and 1/1.2, respectively ( Figure 5 ). Similar data were obtained for the FLIP/Bax ratios (data not shown). In aggregate, these results suggest that RAPA up-regulated expression of the survival molecules in Treg, while in CD4 + CD25 neg T cells it up-regulated expression of the proapoptotic molecules. The data support the hypothesis that RAPAinduced apoptosis may be the mechanism responsible for a demise of CD4 Figure 6A ). The levels of phospho-STAT5 were up-regulated upon 4 h incubation+1 nM RAPA in CD4 + CD25 high T cells of all 6 NC but only moderately in CD4
+ CD25 neg cells of 2/6 NC. At the higher RAPA concentration (50 nM) phospho-STAT5 levels tended to decline. 
CD25
neg T cells (Table 4 ). The addition of RAPA had a more dramatic effect on STAT3 signaling in CD4
high cells, as levels of phospho-STAT3 increased throughout the culture period ( Figure 7D ). No such increase was seen in CD4 + CD25 neg cells +RAPA ( Figure 7C ). These signalling data are correlated to proliferation and suppression activity of the relevant cell subsets in Table 4 .
Overall, the above data indicate that RAPA-driven proliferation of CD4
+
CD25
high Treg is dependent on the STAT pathway. In contrast, CD4 +
neg T cells did not signal via STATs whether in the presence or absence of RAPA.
Elevated PTEN expression in RAPA-expanded CD4 + CD25 high cells PTEN is a known negative regulator of the PI3K/mTOR pathway [30] . It has been reported that in mice, high PTEN levels are responsible for resistance of Treg to RAPA-induced apoptosis [31] . Therefore, we studied PTEN expression levels in human SCS CD4
+ CD25 high and conventional CD4 + CD25 neg T cells6-RAPA, with the expectation that the former will express high levels of PTEN. About half of freshly isolated CD4 + CD25 high and CD4 + CD25 neg T cells expressed PTEN. In cultures +RAPA, the percent of PTEN +
CD4
+ CD25 high T cells gradually increased to reach close to 100% in 3 week cultures ( Figure 8A ). The MFI was also significantly higher in fresh CD4 + CD25 high T cells, and in culture, the high level of PTEN expression (MFI) remained significantly higher than that in cultured CD4 + CD25 neg T cell subsets used in these experiments are shown in Figure 8B . These data are consistent with the hypothesis that a high level of PTEN expression in Treg is important for their resistance to RAPA-induced cell death.
PI3K/Akt/mTOR signalling in Treg
High levels of PTEN seen in Treg suggest that this survival pathway may be blocked in these T cells. To further examine this possibility, we studied phospho-Akt mTOR, phosphorylated mTOR expression and downstream phosphorylation of 4E-PB1 and p70S 6K1 in CD4 + CD25 high and CD4 + CD25 neg T cells. Western blot analyses showed that mTOR protein levels were comparable in the freshly-isolated T-cell subsets and remained unchanged in the presence of RAPA (data not shown). Phosphorylation of Akt, upstream of mTOR, was negligible in fresh CD4
+ CD25 high T cells relative to that in CD4 + CD25 neg T cells ( Figure 8D ). When phosphorylation of the downstream targets, 4E-BP1 and p70S6K1, was examined in Western blots, low or no expression of the phosphorylated proteins was evident in fresh CD4
high T cells. In contrast, their expression was high in fresh CD4 +
CD25
neg T cells as was that of phospho-Akt. By flow cytometry ( Figure 8E ), the baseline expression of phosphorylated 4E-BP1 and p70S6K1 proteins was higher in the CD4 + CD25 neg T cells than the CD4
high cells, and after OKT3 and IL-2 stimulation, it was substantially upregulated only in the CD4 + CD25 neg cells. In RAPA-containing cultures of these cells, the expression of phosphorylated proteins in both the T cell subsets was blocked ( Figure 7D ). The data are consistent with the model suggesting that Treg do not utilize the PI3K/mTOR pathway, because it is down-regulated by PTEN, while proliferation and survival of CD4 + CD25 neg conventional T cells depend on this pathway and are inhibited by RAPA.
Discussion
For many years, RAPA (sirolimus) has been used as an immunosuppressive drug that induces peripheral tolerance, although the mechanism of its action is still not completely understood. Specifically, little is known about the effects of RAPA on expansion, function and survival of Treg subsets in man, although in vitro and in vivo studies of murine Treg have provided insights into molecular pathways that regulate Treg expansion [reviewed in 32]. We and others have reported that RAPA has potentiating effects on CD4 +
CD25
+ Treg [16, 22, 23, 25] . The notion that RAPA may induce tolerance via expansion of Treg numbers and enhancement of their function has introduced a novel paradigm into RAPA activity as an immunosuppressive drug.
In the present work, we demonstrate that in human PBMC obtained from normal donors, RAPA selectively promotes activation and expansion of highly suppressive CD4 + CD25 high -Foxp3 + Treg cells. These cells are resistant to apoptosis, while activated conventional CD4 + CD25 neg T cells become highly sensitive to RAPA, which has been reported to block the survival PI3K/Akt/mTOR pathway these cells preferentially utilize [31] . Thus, responses to activation-induced cell death of human Treg and Tconv appear to be divergently regulated in the presence of RAPA. The CD4 +
high Treg up-regulate expression of the anti-apoptotic Bcl-2 family members (i.e., Bcl-2 and Bcl-xL) in the presence of RAPA, while the conventional CD4 + CD25 neg T cells significantly down-regulate expression of Bcl-2 or Bcl-xL increasing the relative levels of pro-apoptotic Bax and thus promoting apoptosis of this subset of T cells. The resulting shift in the Bcl-2/ Bax or Bcl-xL/Bax ratio favoring anti-apoptotic proteins in the CD4 + CD25 high T cells cultured with RAPA could be responsible for resistance of Treg to apoptosis. Thus, our results provide a rationale for the use of RAPA in order to expand human Treg that are resistant to apoptosis and have potent suppressor functions. Earlier data in mice have also suggested that RAPA might be used in vivo to expand Treg subsets, while depleting the excess of conventional T cells [31] . The definition of optimal conditions for RAPA-driven Treg proliferation is an important objective, because Treg are a minor component of peripheral blood lymphocytes. The ability to reproducibly generate cultures of pure, well-defined and highly suppressive Treg for adoptive transfers to patients with autoimmune diseases or after transplantation in the future remains a challenge. While Treg expansion from cord blood has been previously described [18, 20, 21] and is currently used for therapy to prevent post-transplant graft versus host disease (GVHD), transfers of autologous, adult blood-derived Treg are preferable in today's regulatory climate and also more feasible.
Expression of CD25 (IL-2Ra) on human nTreg suggest that these cells are dependent on IL-2 for proliferation and survival. Signaling via CD25 is crucial for the Treg development and function [31] , and no Treg are present in mice that are IL-2 deficient [33, 34] , IL-2Ra-deficient [34] or IL-2Rb-deficient [35] . Further, IL-2 directly regulates Foxp3 expression and proliferation of human Treg via the STAT pathway [36] . Similarly, cytokine production and proliferation of murine Treg has been shown to be mainly STAT5-dependent [37] . In T cells, signaling downstream of the IL-2R can proceed via the PI3K/Akt/mTOR or JAK/ STAT pathways. While RAPA inhibits the mTOR/PI3K pathway in Treg, JAK/STAT signaling is not affected, sparing Treg from RAPA-induced apoptosis [38] . The significant role of Akt-mTOR pathway in regulating de novo differentiation of CD4 + FOXP3 + Treg has been emphasized by Haxhinasto et al [39] . Battaglia and colleagues have speculated that RAPA may have an inhibitory effect on IL-2 production by activated Tconv, and that Treg able to effectively compete for IL-2 are favored to expand in the presence of RAPA [40] [41] [42] . While murine experiments indicate that IL-2 is required for expansion of Treg, we have shown that IL-2 up-regulates expression of Bcl-2 and Foxp3 in human Treg and that Treg suppressor functions depend on the IL-2 concentration in their microenvironment [43] . Our data demonstrating that RAPA enriches for CD4 + CD25 high T cells with a high expression level of Foxp3 are consistent with this paradigm. Expansion of IL-2 and TCR-activated Treg is regulated by STAT5. The Foxp3 promoter has been shown to contain consensus sequences which bind STAT5, resulting in high levels of STAT5 expression in Treg [36] . Interestingly, STAT3 signaling also appears to be up-regulated in CD3 
high cells by RAPA. In aggregate, these in vitro results with human Treg support a large body of murine data which indicate that in Treg, the STAT signalling pathway is preferentially utilized over the PI3K pathway.
PTEN is an oncogene involved in regulation of a broad variety of cellular functions, including cell proliferation and cell death [31] . PTEN is a negative regulator of the mTOR pathway, and it inhibits IL-2R-mediated expansion of CD4 + CD25 + Treg [44] . Elevated PTEN levels observed in human Treg suggest that these cells have a reduced usage of the PI3K/mTOR pathway, in contrast to CD4 + CD25 neg Tconv, which depend on the PI3K pathway for their proliferation and survival. If PTEN blocks downstream events in the PI3K pathway in CD4 + CD25 high T cells, then the reduced expression of phosphorylated mTOR and phosphorylated 4E-BP1 and p70S6K1 proteins should be evident in these cells relative to CD4 + CD25 neg Tconv. Indeed, our results confirm this hypothesis and suggest that Treg depended on the IL-2R-mediated JAK/STAT signaling for proliferation, so that it is not inhibited by RAPA. In contrast, CD4 +
neg Tconv responding to TCR and IL-2 stimulation signals via the PI3K pathway are sensitive to RAPA-induced inhibition of proliferation. Recent data of Buckler at al in mice suggest that by negatively regulating TCR-mediated signals, PTEN imposes a requirement for CD28 co-stimulation to assure T-cell proliferation and survival [45] . Their observation together with our finding that PTEN is highly expressed in human CD4 +
high Treg might explain why human postthymic Treg expanded in vitro in the presence of RAPA require CD28 co-stimulation for survival and suppressor function in vivo [46] . In this context, the CD28-PTEN pathway might represent a novel regulation mechanism of peripheral tolerance mediated by Treg. The observations we report for human Treg endorse the molecular models of Treg signaling proposed for murine T cells [25, 30] . As Treg play a critical role in control of autoimmune diseases, transplant rejection and cancer, a better understanding of molecular signaling they utilize is essential for improving therapeutic interventions in these diseases. While the precise molecular mechanisms operating the survival or death pathways in T cells are still under investigations, the possibility of their pharmacologic manipulation in the future might open the way for the development of new immunotherapeutic strategies that will permit the ''long-term'' induction and selective expansion of Treg or provide clues about their selective elimination. The permanent depletion of Treg in patients with cancer or infectious diseases might be beneficial, allowing for expansion of T effector and helper T cells and circumventing the side effects of current therapies Figure 5 . Expression levels the anti-apoptotic (Bcl-2 and Bcl-xL) and the pro-apoptotic (Bax) proteins in CD4
neg T cells measured before and after culture in the presence or absence of RAPA. The data are mean fluorescence intensity (MFI) mean values (6SD) for Bcl-2, Bcl-xL and Bax expression levels obtained from measurements with freshly isolated T-cell subsets or T-cell subsets cultured with RAPA or without RAPA. The ratios of Bcl-2/Bax or Bcl-xL/Bax are above the histograms. T cell subsets were separated by MACS from PBMC of 10 NC and cultured as described in Materials and Methods. doi:10.1371/journal.pone.0005994.g005 which cause general immunosuppression by depleting all activated T cells.
Materials and Methods
Media and reagents
All cell culture reagents, including AIM V, DMEM, RPMI 1640 media, phosphate-buffered saline (PBS), streptomycin (S), penicillin (P), sodium pyruvate L-glutamine, non-essential amino acids, and trypan blue dye were purchased from Gibco/ Invitrogen, Grand Island, NY. Culture media, were supplemented with pre-tested human AB serum (8%, v/v) purchased from Geminie Bioproducts (West Sacramento, CA), penicillin (100 IU/ mL), streptomycin (100 mg/mL) and L-glutamine (2 mM/L) and cell cultures were incubated at 37uC in an atmosphere of 5% CO 2 in air. Recombinant human IL-2 (rh IL-2) was purchased from Peprotech, Rocky Hill, NJ. Anti-CD3 mAb (OKT3) was obtained from ATCC, Rockville, MD. Anti-CD3 and anti-CD28 mAbcoated beads were from Beckman Coulter, Miami, FL. Rapamycin (RAPA), saponin and Brefeldin A were from Sigma, St. Louis, MO. Recombinant human (rh) IL-6 was purchased from Cellgenix, Antioch, IL.
Antibodies for flow cytometry
The following anti-human mAbs were used for flow cytometry analysis: anti-CD3-ECD, anti-CD4-PC5, anti-CD25-FITC and -PE, anti-CD122-FITC, anti-CD132-PE, anti-CD45RO-FITC, anti-Fas-FITC, anti-IFNc-FITC, anti-CD62L-FITC and anti-CD152-PE were purchased from Beckman Coulter, (Miami, FL); anti-h/TNFRSF18-GITR (clone FAB689F) and anti-CCR7-FITC from R&D Systems, Inc., (Minneapolis, MN) ; anti-TGF-b 1 (unconjugated) was from Antigenix America, Inc., (Huntington Station, NY); anti-Foxp3-FITC (clone PCH101); anti-IL-4-FITC and anti-CD127-FITC from eBioscience (San Diego, CA); antiFasL-PE (NOK-1.42 kDa) and anti-Perforin-FITC from Biolegend (San Diego, CA); anti-Granzyme B-PE (clone GB111) from PeliCluster Inc, (Netherlands) and anti-Granzyme A-PE, anti-CD45RA-FITC, anti-IL-10-PE and isotype controls IgG 1 , IgG 2a as a secondary Ab. Prior to use, all mAbs were titrated using normal resting or activated PBMC to establish optimal staining dilutions.
Cell isolation and separation
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained from 21 normal donors (Central Blood Bank of Pittsburgh) on Ficoll-Hypaque density gradients (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Cells recovered from the gradient interface were washed twice in RPMI 1640 medium, counted and separated into monocytes and lymphocytes via plastic Table 4 . doi:10.1371/journal.pone.0005994.g007
adherence. The non-adherent fraction was immediately used for magnetic cell isolation using AutoMACS (Miltenyi Biotec, Auburn, CA) as previously described [16] 
Expansion of human CD4
+ CD25 + Treg
Using a previously developed protocol [16] , we cultured MACS-isolated T cells in the presence of anti-CD3/CD28 Abcoated beads and IL-2 [16, 27] . Briefly, purified CD4
+ CD25 neg T cells (1610 5 cells/well) were initially cultured in 96-well plates in AIM V medium supplemented with soluble OKT3 (1 mg/mL), IL-2 (150 IU/mL) and irradiated (3,000R) autologous feeder cells (2 feeder cells to 1 Treg) for 5 to 7 d. Next, the cells were transferred to wells of a 24-well plates (at least 2.5 to 3610 5 cells/well) and restimulated with anti-CD3/CD28 mAb-coated beads (1 viable cell to 4 beads). On the 3rd day, IL-2 (1,000 IU/mL) was added and the cells were cultured for 7-8 days. On Day 8, the cells were re-stimulated with anti-CD3/CD28 mAb and IL-2 (1,000 IU/mL) and RAPA at the final concentration of 1, 10, 50 or 100 nM was added to half of the cultures. Cultures were supplemented with fresh medium plus RAPA as needed. After 3 weeks of expansion in the presence of RAPA the beads were removed using a magnet and the cells counted. Cells (at least 6610 5 cells/well) were transferred to wells of 6-well plates and again re-stimulated with anti-CD3/CD28 mAb-coated beads and 1,000 IU/mL IL-2 in the presence or absence of RAPA for 1-2 weeks. On the final day of culture anti-CD3/ CD28 mAb-coated beads were removed, cells were washed in medium, counted in the presence of a trypan blue dye and resuspended in medium containing 50 IU/mL of IL-2 for 24-48 h prior to all phenotypic or functional assays. Expanding T cells were routinely analyzed at 3 different time points: at weeks 1, 3 and 6. R0 are cultures of CD4 + CD25 + or CD4 + CD25 neg T cells in the absence of RAPA, while+R are cultures of these T cell subsets+RAPA.
Surface and intracellular staining
After harvest, cells were washed and stained with the above listed Abs for 15 min at 4uC as previously described [16, 28] . Appropriate isotype control Abs were used for each sample. Following staining, cells were examined by four-color flow cytometry.
Intracellular staining was performed as previously described [16] . Expression levels of TGF-b 1 , IL-10, Foxp3, CTLA-4, BcL-2, Bax, BcL-xL, PTEN, 4E-PB1 and p70S6K1 were assessed before and after activation of cells with anti-CD3/CD28 beads and IL-2 (6RAPA). Briefly, samples were first incubated with mAbs against surface markers. After washing, cells were fixed with 4% (v/v) paraformaldehyde in PBS for 20 min at RT, washed once with flow solution (PBS containing 0.5% (v/v) BSA and 2 nM EDTA), permeabilized with PBS containing 0.5% BSA (v/v) and 0.1% (v/ v) saponin and stained with detection Abs specific for intracytoplasmic proteins for 30 min at RT. Cells were further washed twice with PBS containing 0.5% BSA (v/v) and 0.2% (v/v) saponin, fixed with 4% (w/v) paraformaldehyde and analyzed by flow cytometry. Appropriate isotype controls were included for each sample. Cells stained with the primary unconjugated Ab were incubated with the secondary Ab (anti-rabbit-FITC-IgG, 1500 ng/mL) purchased from Jackson ImmunoResearch Laboratories Inc., West Grove, PA, or with a control secondary Ab (antimouse-FITC-IgG at 1:10 dilution; Beckman Coulter) in saponin for 15 min, washed twice with PBS containing 0.5% BSA and 0.2% (v/v) saponin and analyzed by flow cytometry.
Suppression assays
Responder CD4
+ CD25 2 T cells (RC) were autologous to suppressor cells (S). Freshly-isolated RC were cryopreserved. Prior to their use in suppression assays, RC were thawed and maintained in medium plus 50 IU/mL of IL-2 for 48 h. RC were stained with 1.5 mM CFSE (Molecular Probes/Invitrogen, Carlsbad, CA) as previously described [16] and co-cultured with S in a complete AIM V medium containing IL-2 (150 IU/mL), plate-bound OKT3 (1 mg/mL) and soluble anti-CD28 Ab (1 mg/ mL) in wells of 96-well plates (at least 5610 5 /well). S were CD4 + CD25 high or CD4 + CD25 neg T cells expanded6RAPA under conditions described above for 3-6 weeks and added to RC at the S:R ratios of 1:1, 1:5 and 1:10. Co-cultures were incubated at 37uC in an atmosphere of 5% CO 2 in air for 3-5 d. After harvest, suppression of CFSE-labeled RC proliferation was analyzed. Data obtained by flow cytometry were analyzed as previously described by us [3, 5, 16] using ModFit LT for Win32 software provided by Verity Software House, Inc., Topsham, ME. The percentages of suppression were calculated based on the proliferation index (PI) of RC alone compared with the PI of cultures containing RC and Treg. The program determines the percent of cells within each peak, and the sum of all peaks in the control culture is taken as 100% of proliferation and 0% of suppression.
Annexin V binding
The binding of ANX V-FITC (Apoptosis Detection Kits, BD PharMingen) to phos-phatidylserine on T-cell surface was used as a measure of apoptosis. Stained samples were analyzed by flow cytometry. The gates were set to include the live (PI-) as well as the dead (PI+) cells present in each sample. The proliferation fold and percent suppression (at the 1:1 ratio of Treg to RC) observed in 3 week cultures of Treg obtained from the 6 NC, whose Treg and Tconv were tested for phospho-STAT3 and phospho-STAT5 as shown in Figure 7 . The data are mean percentages6SD. Asterisks indicate significant differences between no RAPA and+RAPA cultures at p,0.001. doi:10.1371/journal.pone.0005994.t004 (20 min) stimulation with 150 IU/mL IL-2 (STAT5-expression) or 150 IU/mL IL-6 (STAT3-expression). Cells were cultured6RAPA for a short (4 hr) or longer time periods (1, 2, 3 or 4 weeks), harvested, washed, stimulated with the cytokines for 20 min and then stained for analysis with anti-CD3-ECD, anti-CD4-PC5 and anti-CD25-PE Abs followed by intracellular staining with the anti-phosphorylated STAT5 Ab (pY694) labeled with Alexa Fluor-488 or the Ab specific for phosphorylated STAT3 Ab (pY705)-Alexa Fluor-488 (both from BD Biosciences). The gate for flow cytometry was set on CD3 +
Expression of phosphorylated STAT3/5 proteins
CD4
+ cells and then on CD25 neg or CD25 high cells.
Western blot analysis
Cells (CD4 + CD25 + and CD4 + CD25 neg ) were lysed at 4uC at the concentration of 0.5610 6 cells/mL. The lysis buffer, SDS-PAGE electrophoresis and blotting conditions were as previously described [29] . Membranes were washed and probed with the following polyclonal Abs, all purchased from Cell Signaling: phospho-p70S6Kinase (Thr 389); phospho-4E-BP1 (Thr 37/47); mTOR (7Clo) rabbit mAb; phospho-mTOR (Ser 2448); phosphomTOR (Ser 2481); phospho-PI3Kp85 (Tyr 458)/p55. Blots were visualized by ECL (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. For reprobing, Abs were first stripped using Restore Western Blot stripping buffer (Pierce, Rockford, IL) and then the membranes were blotted with the second Ab.
Statistical Analysis
The arithmetic means and SD values were calculated for all parameters in at least ten independent experiments. Statistical analysis of differences in all of the data was done using the one-way ANOVA test. P values ,0.05 were considered significant.
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